Is regression to normoglycaemia clinically important?

The Lancet

Volumn 379, Issue 9833, 2012, Pages 2216-2218

  Yakubovich, Natalia ^a   Gerstein, Hertzel C ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLUCOSE; METFORMIN; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; VOGLIBOSE;

BLINDNESS; DIET; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; LIFESTYLE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RELAPSE; REMISSION; RISK; VASCULAR DISEASE;

EID: 84862283195     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60828-9     Document Type: Note

References (13)

1. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78: 305-12.
2. Perreault L, Kahn SE, Christophi CA, et al. Regression from pre-diabetes to normal glucose regulation in the Diabetes Prevention Program. Diabetes Care 2009; 32: 1583-88.
3. Snehalatha C, Mary S, Selvam S, et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1). Diabetes Care 2009; 32: 1796-801.
4. Ramachandran A, Snehalatha C, Mary S, et al. Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2). Diabetologia 2009; 52: 1019-26.
5. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364: 1104-15.
6. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-105.
7. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-62.
8. Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010; 376: 103-11.
9. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373: 1607-14.
10. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-77.
11. Perreault L, Pan Q, Mather KJ, Watson KE, Hammam RF, Kahn SE, for the Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012; published online June 9. DOI:10.1016/S0140-736(12)60525-X.
12. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on βcell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1753-60.
13. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care 2009; 32: 2133-35.